Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors

Area of Science:

• Oncology
• Molecular Diagnostics
• Cancer Therapeutics

Background:

• The treatment of advanced malignancies has evolved significantly with targeted therapies and immunotherapies, improving outcomes for some patients.
• Identifying patients likely to benefit from these treatments is crucial to minimize toxicity and healthcare expenses.
• Cell-free circulating tumor DNA (ctDNA) is a non-invasive biomarker used for tumor genotyping in various cancers.

Purpose of the Study:

• To review the predictive value of molecular response, defined by early on-treatment changes in ctDNA, for patient outcomes in advanced cancer.
• To summarize the current scientific understanding, clinical applications, and future directions for molecular response as a predictive tool.

Main Methods:

• Review of existing scientific literature on ctDNA and molecular response in advanced malignancies.
• Analysis of the application of ctDNA monitoring for real-time assessment of therapeutic response.
• Discussion of the potential of molecular response in predicting clinical benefit and patient outcomes.

Main Results:

• Early changes in ctDNA levels during treatment (molecular response) can serve as a sensitive indicator of therapeutic efficacy.
• ctDNA's short half-life allows for timely assessment of treatment response, unlike traditional methods.
• Molecular response has shown promise in predicting long-term outcomes for patients with advanced cancers.

Conclusions:

• Molecular response using ctDNA is a valuable tool for real-time prediction of treatment outcomes in advanced cancer.
• Further development and validation are needed to fully integrate molecular response into routine clinical practice for personalized cancer care.
• This approach holds potential for optimizing treatment strategies, reducing adverse effects, and improving patient survival.